Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2015, Article ID 817578, 4 pages
Case Report

Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?

1Department of Hematology and Oncology, Cleveland Clinic, 9500 Euclid Avenue R35, Cleveland, OH 44195, USA
2Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue J3-4, Cleveland, OH 44195, USA

Received 16 July 2015; Accepted 30 September 2015

Academic Editor: Raffaele Palmirotta

Copyright © 2015 Bo Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Agents targeting vascular endothelial growth factor (VEGF) represent active drugs in treating patients with advanced renal cell carcinoma (RCC). Studies have shown that sunitinib and axitinib can be associated with cardiac toxicity. Whether these agents should be restarted in patients who experience cardiac ischemia remains uncertain. Here, we present three patients with metastatic RCC who restarted sunitinib or axitinib after intervention of active ischemic cardiac disease without causing subsequent relevant cardiac events. This experience suggests that these agents can be continued after management of cardiac ischemia.